Anurag Singh

Anurag Singh

MD

Specializing In:

Breast cancer Head and neck cancer Lung cancer Prostate cancer

Special Interests:

SBRT (Stereotactic Body Radiation Therapy) Novel agents to improve radiation therapy Novel agents to protect against side effects of radiation therapy Development and implementation of imaging to improve radiation targeting Methods to improve quality of life following radiation therapy Impact of nutrition on patient outcomes


Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Professor of Oncology
  • Director of Radiation Research, Department of Radiation Medicine
  • Co-Leader, Cell Stress and Biophysical Therapy Program
  • Associate Dean of Graduate Medical Education, Research
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
  • Professor of Medicine

Background

Education and Training:

  • MD - Washington University School of Medicine, St. Louis, MO
  • BS - Yale University

Residency:

  • Mallinckrodt Institute of Radiology, St. Louis, MO

Board Certification:

  • Radiation Oncology, American Board of Radiology

Professional Experience:

  • 09/2012 - Present: Professor of Medicine, University at Buffalo
  • 07/2012 - Present: Professor of Oncology, Director of Radiation Research, Roswell Park Cancer Institute
  • 07/2007 – 07/2012: Associate Professor, Director of Radiation Medicine Residency Program, Director of Radiation Research, Roswell Park Cancer Institute, University at Buffalo
  • 07/2004 - 06/2007: Attending Physician, Head of Molecular Imaging Section, Radiation Oncology Branch, National Cancer Institute

Honors & Awards

  • 2013-19 - Top Doctors in Western New York (Castle Connolly)
  • 2017 - ASTRO Basic/Translational Science Abstract Award, Sr. Investigator in the Clinical category for, “A Pilot Study of Stereotactic Body Radiation Therapy Combined With Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.”
  • 2016 - Walter T. Murphy Educator of the Year Award given by the Radiation Medicine residents for excellence in clinical education
  • 2016 - Commendation from ACGME Residency Progam Review: No citations & excellent compliance
  • 2015 - Commendation from ACGME Residency Progam Review: No citations & excellent compliance
  • 2011 Outstanding Accreditation Award from University at Buffalo, No citations and Commendable Practice ACGME Residency Program Review
  • 2010 - Educator of the Year (2009-2010), Association of Residents In Radiation Oncology (ARRO)
  • 2006 - CaPSure Mentor (for Nicole SImone)
  • 1995 - MENSA Research and Education Scholarship
  • 1995 - Magna Cum Laude Graduate, Yale University
  • 1994 - MENSA Research and Education Scholarship
  • 1994 - Xerox Technical Merit Scholarship

Research

Research Overview:

Research Projects:

09/2009 -- Present

Radiation therapy Oncology Group (RTOG) A Randomized Phase II Study, A Randomized Phase II Study Comparing 2 Sterotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage I, Peripheral Non-Small Cell Lung Cancer (34 Gy x 1 vs 12 Gy x 4) (co-PI with G. Videtic and J. Chang)

11/2008 -- Present

RPCI-A feasibility of study of re-irradiation using SBRT, A feasibility of study of re-irradiation using stereotactic body radiation therapy (SBRT) and concurrent cisplatin, fluorouracil, and cetuximab for recurrent squamous cell carcinoma of the head and neck (SCCHN)

04/2008 -- Present

RPCI- A Phase II Randomized Study of 2 SBRT Regimens, A Phase II Randomized Study of 2 Sterotactic Body Radiation Therapy (SBRT) Regimens for Medically Inoperable Patients with Node Negative, Peripheral Non-Small Cell Lung Cancer (30 Gy x 1 vs 20 Gy x 3)

09/2007 -- Present

RPCI MR Imaging to Stratify Prostate Cancer Progression Risk, MR Imaging to Stratify Prostate Cancer Progression Risk in Patients On Active Surveillance

09/2005 -- Present

NCI-A Pilot Study of Image Guided Prostate and Pelvic Irradiation, National Cancer Institute (NCI) - A Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation with Intensity Modulated Radiation Therapy (IMRT) (Current PI: A Kaushal)

05/2005 -- Present

NCI-A Phase I Study of Image Guided Dose Escalation with IMRT, National Cancer Institute (NCI) A Phase 1 Study of Image Guided Dose Escalation with Intensity Modulated Radiation Therapy (IMRT) to Histologically Confirmed Regions of Prostate Cancer (Current PI: A Kaushal)

06/2003 -- Present

Wash.Univ.- A Phase II study of extended field external beam irradiation, Washington University, Saint Louis - A Phase II study of extended field external beam irradiation and intracavitary brachytherapy with concurrent weekly cisplatin in patients with stage 1-IV a cervical cancer who have FDG-PET positive pelvic or para-aortic nodes (Current PI: P Grigsby)


Publications

Dr. Singh has over 100 publications. The full list can be found here.

Below are some representative publications:

  1. Sio TT, Le-Rademacher JG, Leenstra JL, Loprinzi CL, Rine G, Curtis A, Singh AK, Martenson JA Jr, Novotny PJ, Tan AD, Qin R, Ko SJ, Reiter PL, Miller RC. Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial. JAMA. 2019 Apr 16;321(15):1481-1490. doi: 10.1001/jama.2019.3504. PubMed PMID: 30990550; PubMed Central PMCID: PMC6484809.
  2. Singh AK, Hennon M, *Ma SJ, Demmy TL, Picone A, Dexter EU, Nwogu C, Attwood K, Tan W, *Hermann GM, Fung-Kee-Fung S, Malhotra HK, Yendamuri S, Gomez-Suescun JA. A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer. BMC Cancer. 2018 Nov 29;18(1):1183. doi: 10.1186/s12885-018-5039-5. PubMed PMID: 30497431; PubMed Central PMCID: PMC6267846.
  3. Chen GL, Hahn T, Wilding GE, Groman A, Hutson A, Zhang Y, Khan U, Liu H, Ross M, Bambach B, Higman M, Neppalli V, Sait S, Block AW, Wallace PK, Singh AK, McCarthy PL. Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity. Biol Blood Marrow Transplant.2019 Apr;25(4):689-698. doi: 10.1016/j.bbmt.2018.09.042. Epub 2018 Oct 6. PubMed PMID: 30300731; PubMed Central PMCID: PMC6451676.
  4. *Iovoli AJ, *Platek AJ, *Degraaff L, Wang C, Duncan WD, Wooten KE, Arshad H, Gupta V, Kuriakose MA, Hicks WL Jr, Platek ME, Singh AK. Routine surveillance scanning in HNSCC: Lung screening CT scans have value but head and neck scans do not. Oral Oncol. 2018 Nov;86:273-277. doi: 10.1016/j.oraloncology.2018.10.008. Epub 2018 Oct 11. PubMed PMID: 30409312.
  5. Singh AK, *Winslow TB, Kermany MH, Goritz V, Heit L, Miller A, Hoffend NC, Stein LC, Kumaraswamy LK, Warren GW, Bshara W, Odunsi K, Matsuzaki J, Abrams SI, Schwaab T, Muhitch JB. A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2017 Sep 1;23(17):5055-5065. doi: 10.1158/1078-0432.CCR-16-2946. Epub 2017 Jun 19. PubMed PMID: 28630212; PubMed Central PMCID: PMC5581708.
  6. *Platek ME, *McCloskey SA, *Cruz M, Burke MS, Reid ME, Wilding GE, Rigual NR, Popat SR, Loree TR, Gupta V, Warren GW, Sullivan M, Hicks WL Jr, Singh AK. Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. Head Neck. 2013 May;35(5):684-8. doi: 10.1002/hed.23024. Epub 2012 May 22. PubMed PMID: 22619040; PubMed Central PMCID: PMC5061340.